Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia

A study published in the Journal of Clinical Oncology presents a molecular-based ecosystem designed to improve personalized medicine approaches for patients with chronic myelomonocytic leukemia (CMML). CMML is a rare and heterogeneous myelodysplastic/myeloproliferative neoplasm with limited treatment options and variable clinical outcomes. The proposed framework integrates molecular profiling data to better stratify patients and guide individualized therapeutic decisions. This work represents an important step toward precision oncology in a disease where standardized molecular tools have been lacking. The ecosystem may help clinicians identify optimal treatment strategies based on each patient's unique genetic landscape.